These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2094334)

  • 21. New concepts of iron and aluminium chelation therapy with oral L1 (deferiprone) and other chelators. A review.
    Kontoghiorghes GJ
    Analyst; 1995 Mar; 120(3):845-51. PubMed ID: 7741239
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A multi-center safety trial of the oral iron chelator deferiprone.
    Cohen A; Galanello R; Piga A; Vullo C; Tricta F
    Ann N Y Acad Sci; 1998 Jun; 850():223-6. PubMed ID: 9668543
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation of iron exchange between the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one(L1) and transferrin and possible antianaemic effects of L1 in rheumatoid arthritis.
    Vreugdenhil G; Swaak AJ; de Jeu-Jaspers C; van Eijk HG
    Ann Rheum Dis; 1990 Nov; 49(11):956-7. PubMed ID: 2256752
    [No Abstract]   [Full Text] [Related]  

  • 24. Use of deferiprone for iron chelation in patients with transfusion-dependent thalassaemia.
    Jamuar SS; Lai AH; Tan AM; Chan MY; Tan ES; Ng IS
    J Paediatr Child Health; 2011 Nov; 47(11):812-7. PubMed ID: 21902752
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospects for effective oral iron chelation therapy in man with 1,2-dimethyl-3-hydroxypyrid-4-one and other alpha-ketohydroxypyridines.
    Kontoghiorghes GJ; Bartlett AN; Hoffbrand AV
    Prog Clin Biol Res; 1989; 309():107-14. PubMed ID: 2780745
    [No Abstract]   [Full Text] [Related]  

  • 26. Urinary iron excretion depends on the mode of administration of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with homozygous beta-thalassemia.
    Fassos FF; Klein J; Fernandes D; Matsui D; Olivieri NF; Koren G
    Clin Pharmacol Ther; 1994 Jan; 55(1):70-5. PubMed ID: 8299320
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes.
    Cermak J; Jonasova A; Vondrakova J; Cervinek L; Belohlavkova P; Neuwirtova R
    Leuk Res; 2013 Dec; 37(12):1612-5. PubMed ID: 23937987
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Agranulocytosis in a patient with thalassaemia major during treatment with the oral iron chelator, 1,2-dimethyl-3-hydroxypyrid-4-one.
    al-Refaie FN; Veys PA; Wilkes S; Wonke B; Hoffbrand AV
    Acta Haematol; 1993; 89(2):86-90. PubMed ID: 8503250
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
    Tanphaichitr A; Kusuwan T; Limviriyakul S; Atipas S; Pooliam J; Sangpraypan T; Tanphaichitr VS; Viprakasit V
    Hemoglobin; 2014; 38(5):345-50. PubMed ID: 25051423
    [TBL] [Abstract][Full Text] [Related]  

  • 30. L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassaemia major.
    Töndury P; Kontoghiorghes GJ; Ridolfi-Lüthy A; Hirt A; Hoffbrand AV; Lottenbach AM; Sonderegger T; Wagner HP
    Br J Haematol; 1990 Dec; 76(4):550-3. PubMed ID: 2265118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone.
    Kolnagou A; Michaelides Y; Kontos C; Kyriacou K; Kontoghiorghes GJ
    Hemoglobin; 2008; 32(1-2):17-28. PubMed ID: 18274979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liver iron depletion and toxicity of the iron chelator deferiprone (L1, CP20) in the guinea pig.
    Wong A; Alder V; Robertson D; Papadimitriou J; Maserei J; Berdoukas V; Kontoghiorghes G; Taylor E; Baker E
    Biometals; 1997 Oct; 10(4):247-56. PubMed ID: 9353871
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of deferiprone (L1) and desferrioxamine on myelopoiesis using a liquid culture system.
    al-Rafaie FN; Wilkes S; Wonke B; Hoffbrand AV
    Br J Haematol; 1994 May; 87(1):196-8. PubMed ID: 7947246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
    Kontoghiorghe CN; Kontoghiorghes GJ
    Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of oral iron chelator L1.
    Hershko C
    Lancet; 1993 Apr; 341(8852):1088-9. PubMed ID: 8096975
    [No Abstract]   [Full Text] [Related]  

  • 36. Oral iron chelation with 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron loaded thalassemia patients.
    Olivieri NF; Matsui D; Liu PP; Blendis L; Cameron R; McClelland RA; Templeton DM; Koren G
    Bone Marrow Transplant; 1993; 12 Suppl 1():9-11. PubMed ID: 8374574
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with thalassemia.
    Matsui D; Klein J; Hermann C; Grunau V; McClelland R; Chung D; St-Louis P; Olivieri N; Koren G
    Clin Pharmacol Ther; 1991 Sep; 50(3):294-8. PubMed ID: 1914364
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Studies of the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one in thalassemia patients.
    Olivieri NF; Koren G; St Louis P; Freedman MH; McClelland RA; Templeton DM
    Semin Hematol; 1990 Apr; 27(2):101-4. PubMed ID: 2190316
    [No Abstract]   [Full Text] [Related]  

  • 39. Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1).
    Rombos Y; Tzanetea R; Konstantopoulos K; Simitzis S; Zervas C; Kyriaki P; Kavouklis M; Aessopos A; Sakellaropoulos N; Karagiorga M; Kalotychou V; Loukopoulos D
    Haematologica; 2000 Feb; 85(2):115-7. PubMed ID: 10681716
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Studies of aluminium mobilization in renal dialysis patients using the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
    Kontoghiorghes GJ; Barr J; Baillod RA
    Arzneimittelforschung; 1994 Apr; 44(4):522-6. PubMed ID: 8011008
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.